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Abstract
Atypical teratoid/rhabdoid tumors (ATRTs) are very aggressive childhood malignancies of the central nervous system. The 
underlying genetic cause are inactivating bi-allelic mutations in SMARCB1 or (rarely) in SMARCA4. ATRT-SMARCA4 
have been associated with a higher frequency of germline mutations, younger age, and an inferior prognosis in comparison 
to SMARCB1 mutated cases. Based on their DNA methylation profiles and transcriptomics, SMARCB1 mutated ATRTs 
have been divided into three distinct molecular subgroups: ATRT-TYR, ATRT-SHH, and ATRT-MYC. These subgroups 
differ in terms of age at diagnosis, tumor location, type of SMARCB1 alterations, and overall survival. ATRT-SMARCA4 
are, however, less well understood, and it remains unknown, whether they belong to one of the described ATRT subgroups. 
Here, we examined 14 ATRT-SMARCA4 by global DNA methylation analyses. We show that they form a separate group 
segregating from SMARCB1 mutated ATRTs and from other SMARCA4-deficient tumors like small cell carcinoma of the 
ovary, hypercalcemic type (SCCOHT) or SMARCA4 mutated extra-cranial malignant rhabdoid tumors. In contrast, medullo-
blastoma (MB) samples with heterozygous SMARCA4 mutations do not group separately, but with established MB subgroups. 
RNA sequencing of ATRT-SMARCA4 confirmed the clustering results based on DNA methylation profiling and displayed 
an absence of typical signature genes upregulated in SMARCB1 deleted ATRT. In summary, our results suggest that, in line 
with previous clinical observations, ATRT-SMARCA4 should be regarded as a distinct molecular subgroup.
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Introduction
Malignant rhabdoid tumors (MRTs) are highly aggressive 
malignancies usually affecting young children and infants. 
They may occur in any part of the body, but the majority 
(66%) is detected in the central nervous system (CNS), 
where they are called atypical teratoid/rhabdoid tumors 
(ATRT) [9]. With an incidence of 1.4 per million in Ger-
many [48], ATRT is a rare tumor entity even in pediatric 
oncology. Still, it is the most common embryonal CNS 
tumor in children younger than 12 months [36, 48]. Inde-
pendent of tumor location, loss of function mutations in 
components of the SWItch/Sucrose Non-Fermentable (SWI/
SNF) chromatin remodeling complex are a characteristic fea-
ture and represent the sole recurrent genetic alteration in all 
MRTs [16, 17, 29]. In the vast majority of MRTs, pathogenic 
variants (hereafter “mutations”) affect the SMARCB1 gene. 
In rare cases (about 0.5–2% of ATRT [12, 22]), SMARCA4 
is mutated instead [17, 42, 43]. Since these mutations result 
in loss of the respective protein, loss of staining for either 
SMARCB1 or SMARCA4 by immunohistochemistry is used 
as a diagnostic tool to ensure the diagnosis of an ATRT [30]. 
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About one-third of patients with SMARCB1-deficient MRTs 
carry germline mutations within the SMARCB1 gene [3, 7, 
20]. Although based on very small numbers, it appears as 
if patients with an ATRT-SMARCA4 are even more often 
carriers of germline mutations. Furthermore, the latter group 
of patients is younger and, as their survival is even shorter, 
their tumors seem to be even more aggressive [17, 20]. How-
ever, due to the small number of patients suffering from an 
ATRT-SMARCA4, accompanied by the lack of suitable 
in vitro and in vivo models, knowledge regarding biologi-
cal mechanisms involved in tumor development is limited. 
Besides MRTs, a role of SMARCA4 has been described for 
a variety of tumor entities including non-small cell lung can-
cer or thoracic sarcomas [28, 39]. In small cell carcinoma 
of the ovary, hypercalcemic type (SCCOHT), loss of the 
SMARCA4 protein has been proposed to be the main driv-
ing event in tumorigenesis [46]. In other tumor types, such 
as Burkitt lymphoma or medulloblastoma (MB), heterozy-
gous missense mutations in SMARCA4 have been identified, 
but their role in tumor development remains elusive [23, 26, 
38, 41].
Recently, DNA methylation profiling has become an 
attractive asset in the diagnostics of CNS tumors [4]. Based 
on global DNA methylation and/or gene expression, ATRTs 
can be divided into three distinct subgroups [15, 22, 47], 
designated as ATRT-TYR, ATRT-SHH, and ATRT-MYC 
[19]. The subgroups differ in the expression of distinct 
genes, the activation of specific signaling pathways, and in 
clinical parameters. For instance, ATRT-TYR, especially 
when older than 12 months, have been associated with a 
slightly better prognosis compared to the other subgroups 
or younger patients [12]. In addition to the subgrouping of 
ATRTs, extra-cranial MRTs (eMRTs) can also be further 
divided into subgroups based on molecular characteristics 
[5, 6]. Of note, DNA methylation profiles of eMRTs share 
many characteristics with ATRT-MYC.
Although these studies helped to increase the knowledge 
of the disease, they were predominantly based on SMARCB1 
mutated ATRTs and eMRTs. Hitherto, three SMARCA4-
deficient cases were included in one of the studies [22] and 
clustered to ATRT-SHH. However, it remains unknown, if 
ATRT-SMARCA4 belong to this subgroup in general, if they 
are divided into the same subgroups as SMARCB1-deficient 
ones, or, if they make up their own subgroup. To address 
these questions, we examined DNA methylation profiles 
and RNA sequencing data. Our results suggest that ATRT-
SMARCA4 should be regarded as a separate molecular 




We used published and unpublished data sets for all analyses 
presented here (Supplementary Table 1, online resource). 
Clinical data for previously unreported cases are summa-
rized in Table 1 as well as in Supplementary Tables 2 and 3, 
online resource. DNA methylation or gene expression data 
from published data sets are available at the gene expression 
omnibus (GEO), accession numbers GSE70678, GSE90496, 
and GSE123601 and/or in the original publications [4–6, 8, 
22, 34, 47]. Diagnosis of the respective tumor entity was 
assured by a (neuro) pathologist. To characterize the individ-
ual SMARCA4 mutations, i.e., predict the respective amino 
acid change, coding impact, and clinical significance/patho-
genicity, we used the search engine VarSome [25]. Predicted 
pathogenicity was based on ClinVar [27] and The American 
College of Medical Genetics and Genomics (ACMG) classi-
fication [40]. Survival of SMARCB1 and SMARCA4 mutated 
ATRTs was compared by performing a log-rank (Mantel-
Cox) test using the Prism Software Version 7 (GraphPad 
Software, Inc. San Diego, USA).
DNA methylation profiling
For DNA isolation from FFPE tissue, 10 × 10 µm sections 
were cut and DNA isolated using the ReliaPrep™ FFPE 
gDNA Miniprep System (Promega) according to manufac-
turer’s instructions. About 100–500 ng DNA was used for 
bisulfite conversion by the EZ DNA Methylation Kit (Zymo 
Research). Afterwards, the DNA Clean & Concentrator-5 
(Zymo Research) and the Infinium HD FFPE DNA Restore 
Kit (Illumina) were employed to clean and restore the con-
verted DNA. Finally, either the HumanMethylation450 
BeadChip array or the Infinium MethylationEPIC BeadChip 
Kit (both Illumina) were used to quantify the methylation 
status of 450,000 or 850,000 CpG sites, respectively, on an 
iScan device (Illumina).
RNA sequencing
For RNA isolation from FFPE tissue, 10 × 10 µm sections 
were cut and RNA isolated using the  Maxwell® RSC RNA 
FFPE Kit (Promega). The RNA integrity was analyzed 
with the RNA 6000 Nano Chip on an Agilent 2100 Bio-
analyzer (Agilent Technologies). From total RNA, the 
ribosomal RNA was depleted with the help of the RiboCop 
rRNA Depletion Kit (Lexogen) followed by RNA sequenc-
ing library generation using the CORALL Total RNA-Seq 
Library Prep Kit (Lexogen). Concentrations of all samples 
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were measured with a Qubit 2.0 Fluorometer (Thermo 
Fisher Scientific) and fragment lengths distribution of the 
final libraries was analyzed with the DNA High Sensitivity 
Chip on an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies). All samples were normalized to 2 nM and pooled at 
equimolar concentrations. The library pool was sequenced 
on the NextSeq500 (Illumina) with 1 × 75 bp, with 24.5–35.1 
million reads per sample.
Bioinformatics
IDAT files were processed as previously described [45]. 
In detail, raw data files were loaded into R using the minfi 
package (v.1.32.0). Since we included data derived from 
EPIC and 450 K arrays, we used single-sample normaliza-
tion method (ssNoob) [10] for normalization of all samples. 
Furthermore, we excluded probes targeting the sex chro-
mosomes. For t-distributed stochastic neighbor embedding 
(t-SNE) analysis, the Rtsne (v.0.15) package was employed. 
Probes were selected by standard deviation > 0.25, resulting 
in 40,426 probes for Fig. 1a and 14,772 probes for Fig. 1b. 
Perplexity was set to 28 and 19 for Fig. 1a, b, respectively. 
The heatmap were build based on the 1000 most variable 
probes by standard deviation with R package pheatmap 
(v1.0.12, https ://CRAN.R-proje ct.org/packa ge=pheat map), 
using the clustering method “ward.D2”. Global DNA meth-
ylation levels were calculated as described in [22] and sig-
nificant differences determined by a Wilcoxon Rank Sum 
Test. Genome-wide chromosomal losses and gains as well 
as gains and losses at the SMARCA4 locus were calculated 
as published previously [6, 37].
Fastq files from single end or paired end sequencing 
were aligned to hg19 human genome using STAR aligner 
(v2.5.2a). Read counts were obtained from the STAR gener-
ated BAM files with featureCounts (v2.0.0) using hg19 gene 
annotation (Ensembl release 87). The count matrix was used 
to obtain normalized reads via variance stabilizing transfor-
mation applied through DESeq2 R package (v1.26.0) and 
then batch corrected using removeBatchEffect function of R 
package limma (v3.42.2). Batch corrections was performed 
between sequencing data generated from FFPE samples (the 
SMARCA4-deficient samples) and the data derived from FF 
samples (SMARCB1 samples).
For t-SNE analysis, we used the packages R-tsne and 
employed only the 500, 1000, and 2000 most variable genes 
throughout all samples. Perplexity was set to 30 and theta 
to 0.5.
For differential expression analysis, we used the DESeq2 
R package and performed correction for multiple testing 
using the Benjamini Hochberg method. For boxplots of 
meaningful, differentially expressed genes, we performed 
ANOVA analysis with post-hoc contrast testing using the 























































































































































































































































































































































































































































































295Acta Neuropathologica (2021) 141:291–301 
1 3
Fig. 1  Unsupervised t-SNE analysis based on the 40,426 most vari-
ant probes of DNA methylation profiles of ATRT-SMARCA4 (n = 14, 
pink), eMRT-SMARCA4 (n = 11, brown), MBs with SMARCA4 
mutation (n = 18, ocher), SMARCB1 mutated ATRTs [n = 62 ATRT-
TYR (dark red), n = 93 ATRT-SHH (blue), n = 53 ATRT-MYC 
(dark green)], eMRT-SMARCB1 (n = 74, purple), SMARCA4 wild-
type MBs [n = 37  MB-WNT (dark blue), n = 135  MB-SHH (red), 
n = 75  MB-Group 3 (yellow), n = 138  MB-Group 4 (green)] and 
SCCOHTs (n = 28, light blue) (a). Unsupervised t-SNE analysis 
based on the 14,772 most variant probes of DNA methylation profiles 
of the same samples but without MB samples (b). Unsupervised t-
SNE analysis based on the 1000 most variable genes across all tumor 
samples, i.e., n = 8 ATRT-SMARCA4 (pink), n = 8 ATRT-TYR (red), 
n = 11 ATRT-SHH (blue) and n = 9 ATRT-MYC (green), Of note, 
ATRT-SMARCA4 cases  10 and 13 displayed strong similarities, as 
their data points almost overlap on the t-SNE plot (c). Significantly 
enriched pathways in ATRT-SMARCA4 are sorted according to 
p-values and depicted in a bar chart (d). Arrow indicates case 7
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GLI2—upregulated only in one of the ATRT subgroups—
we used a t.test of ATRT-SMARC4 versus the subgroups 
ATRT-TYR, ATRT-MYC, and ATRT-SHH. For pathway 
enrichment analysis, we employed the ConensusPathDB tool 
(http://cpdb.molge n.mpg.de/) using the “enrichment analy-
sis” option and default datasets to be tested. Visualization 
was performed using the ClueGo tool (version 2.5.7) from 
Cytoscape using default parameters.
Data availability
The DNA methylation and gene expression data of this study 
have been deposited in NCBI’s Gene Expression Omnibus 
(GEO; http://www.ncbi.nlm.nih.gov/geo) and are accessible 
through GEO Series accession numbers GEO: GSE161692 
and GSE160748, respectively.
Results
ATRT‑SMARCA4 do not group with the known ATRT 
subtypes based on DNA methylation pattern
In this study, we included 8 unpublished and six previously 
reported ATRT samples with a verified SMARCA4 altera-
tion [17, 32, 43]. All clinical data including genetics and 
survival are depicted in Table 1 and Supplementary Fig. 1, 
online resource. We performed global DNA methylation 
analysis of all 14 tumor samples and used the Heidelberg 
Brain Tumor classifier (v11b4) [4] to validate, whether they 
matched to one of the established ATRT subgroups. Fifty 
percent of the samples (7/14) were classified (score > 0.9) as 
an ATRT-SHH, 21% (3/14) showed the best, but not a spe-
cific match with ATRTs (score = 0.58–0.87), whereas 29% 
(4/14) did not match to any methylation class at all. Aiming 
to better characterize our tumor samples in an unsupervised 
way, we performed t-SNE. To this end, we included previ-
ously published and unpublished DNA methylation profiles 
of other SWI/SNF-deficient tumors, i.e., SCCOHTs and 
eMRTs (Supplementary Table 1–2, online resource [5, 6, 
8]). The latter comprised samples with either a SMARCA4 
or a SMARCB1 mutation. Furthermore, we included MBs 
with heterozygous SMARCA4 missense mutations as well 
as SMARCA4 wild-type MBs and further ATRTs (Supple-
mentary Table 3, online resource [4, 34]).
We recognized that MBs with SMARCA4 mutations 
grouped with their annotated MB subgroups (Fig. 1a). 
ATRT-SMARCA4 located close to the SCCOHTs, ATRTs, 
and eMRTs without grouping distinctly to one tumor 
entity. We then removed all MB samples and recalculated 
the t-SNE (Fig. 1b) and additionally performed unsuper-
vised hierarchical clustering (Supplementary Fig. 2, online 
resource). Thereby, we recognized that ATRT-SMARCA4 
arranged as a separate class, whereas the eMRTs with 
SMARCA4 deficiency were located in between the 
SCCOHTs and the SMARCA4 wild-type eMRTs. Case 7 
(arrow in Fig.  1b) grouped with SMARCA4-deficient 
eMRTs instead of ATRTs. However, this patient did 
not only harbor multiple supratentorial lesions, but also 
tumor masses at the left cardiac ventricle and in the right 
proximal femur. Therefore, we cannot rule out that case 
7 is in fact the metastasis of an eMRT. Finally, ATRT-
SMARCA4 had the lowest methylation levels of all ATRTs 
(Supplementary Fig. 3). Taken together, DNA methylation 
patterns of ATRT-SMARCA4 indicate that these tumors 
cannot be included in the established classification of 
SMARCB1 mutated ATRTs.
The transcriptome of ATRT‑SMARCA4 is distinct 
from SMARCB1 altered ATRTs and suggests 
enhanced Ephrin signaling as a possible tumor 
driver
Next, we performed RNA sequencing of 8 ATRT-
SMARCA4 (Table 1) and compared them to SMARCB1 
mutated ATRT by t-SNE analysis (Fig. 1c). We recognized 
four distinct subgroups in the t-SNE plot corresponding 
to ATRT-TYR, ATRT-SHH, ATRT-MYC, and ATRT-
SMARCA4. As expected, SMARCA4 expression levels 
were reduced, whereas SMARCB1 expression levels were 
higher in SMARCA4-deficient tumor samples compared to 
all other ATRT subgroups (Supplementary Fig. 4a,b, online 
resource). SMARCA2, which is supposed to be post-tran-
scriptionally downregulated in SCCOHTs [24], displayed 
lower expression values as well (Supplementary Fig. 4c, 
online resource). Besides these SWI/SNF-related genes, the 
SMARCA4-deficient samples featured high expression values 
of EPHA5, ROCK1, and FGF10 as well as low expression 
levels of GLI2, MITF, MYC, and DMRT2 (Supplementary 
Fig. 4d-j, online resource). Concordantly, functional analy-
sis using ConsensusPathDB [18] identified EPHA forward 
signaling including the genes EPHA5 and ROCK1 as the 
most significant enriched pathway (Fig. 1d). As EPHA5 is 
known to be significantly upregulated in SCCOHT as well 
[1], Ephrin signaling might be one of the tumor-promoting 
pathways in tumors driven by SMARCA4 deficiency. Finally, 
network analysis suggested further processes including 
neuronal function associated terms such as Neuroactive 
ligand-receptor interaction and Membrane depolarization 
to be altered in ATRT-SMARCA4 (Supplementary Fig. 5, 
online resource). Overall, comparing the transcriptomes 
of SMARCA4 and SMARCB1 mutated ATRTs sustains the 
notion that the former forms a separate subgroup marked 
by Ephrin signaling rather than fitting into the established 
ATRT subclasses.
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SMARCA4 deficiency is not the result of large 
chromosomal deletions
The ATRT subgroups ATRT-TYR, ATRT-SHH, and ATRT-
MYC are not only different in regard to their DNA methyla-
tion profiles and their transcriptomes, but also harbor dif-
ferent kinds of tumor-driving SMARCB1 alterations [19]. 
To examine the genetic basis of SMARCA4 deficiency in 
our cohort, we investigated chromosomal gains and losses 
(Supplementary Fig. 6, online resource) and alterations 
specifically at the SMARCA4 locus located on chr19p13.2 
(Supplementary Fig. 7, online resource). As expected, the 
only chromosomal alterations in SMARCB1-deficient ATRTs 
were losses on chromosome 22q, harboring SMARCB1. 
Deletions of chromosomal regions of 4q and 6q were 
detected in SMARCB1 mutated eMRTs. Neither ATRTs nor 
eMRTs nor SCCOHTs displayed large chromosomal altera-
tions, including chromosomal arm 19p. The SMARCA4 locus 
revealed no deletions in any of the examined tumor samples.
Discussion
In this study, we collected 14 samples of ATRT-SMARCA4 
aiming at the molecular characterization of these tumors. 
Based on clinical data, our cohort fits well with all previ-
ously published cases [17], as the patients were very young 
infants, who died shortly after diagnosis. Since we were par-
ticularly interested in whether these tumors belong to one 
or more of the three known ATRT subgroups (ATRT-TYR, 
ATRT-SHH, ATRT-MYC), we performed DNA methyla-
tion and RNA sequencing analysis to examine them on a 
molecular level.
First, only half of our cases were recognized as ATRTs by 
the Heidelberg Brain Tumor classifier. The ones that were 
recognized matched all to ATRT-SHH. This was in line 
with the previously published observation that 3 SMARCA4 
mutant cases matched to ATRT-SHH in an unsupervised 
hierarchical clustering analysis of DNA methylation data 
[22]. Still, 50% of our cases could not be diagnosed using 
the Heidelberger classifier. This uncovers a problem in the 
diagnostics of these tumors, as the classifier has become 
an import neuropathological tool, in particular for rare 
and aggressive brain tumors. In t-SNE analyses, ATRT-
SMARCA4 grouped overall together with SMARCB1-
deficient RTs and SCCOHTs, but did not locate specifically 
within one of these tumor subclasses. Furthermore, they 
clustered apart from the established ATRT subgroups and 
formed a separate subcluster within the group of SMARCA4-
deficient tumors. In contrast, MBs carrying heterozygous 
SMARCA4 missense mutations, clearly grouped together 
with one of the four MB subgroups on t-SNE. This finding 
suggests that in ATRTs the SMARCA4 alterations, which 
are either homozygous nonsense or homozygous missense 
mutations, have a major impact on the tumor’s methylome, 
whereas the heterozygous missense mutations in MB might 
be less important in this regard. SCCOHTs and eMRTs, 
especially those with SMARCA4 deficiency, showed high 
similarities in our analyses, even though not being randomly 
intermingled. Our results are, therefore, in line with previ-
ously published studies discussing whether SCCOHTs shall 
be regarded as a subgroup of RTs [8, 11].
ATRTs and eMRTs with SMARCA4 deficiency as well 
as SMARCB1 mutated eMRTs and ATRT-MYC were hypo-
methylated and differed significantly from the hypermethyl-
ated ATRT-SHH and ATRT-TYR. This finding is in agree-
ment with other studies that have previously investigated 
global methylation levels of SMARCB1-deficient RTs [6, 
19]. Furthermore, SCCOHTs also displayed the lowest meth-
ylation levels, indicating that SMARCA4-deficient tumors 
demonstrate a rather hypomethylated phenotype. This may 
promote tumor development and progression by changing 
the global heterochromatin structure and activating proto-
oncogenes or germline specific genes [31, 49]. Furthermore, 
global hypomethylation is associated with a poor prognosis 
in cancer entities, such as myeloma or type I ovarian cancers 
[35, 44] and increases during the malignant transformation 
of meningioma [13]. This might be associated with the even 
more aggressive behavior of ATRT-SMARCA4 compared 
to SMARCB1 mutated ones.
We identified possible signature genes for ATRT-
SMARCA4, as EPHA5, ROCK1, and FGF10 were up- and 
DMRT2 significantly downregulated in these tumors. The 
most significant enriched pathway was Ephrin forward sign-
aling that is important for embryonic CNS development and 
also known to be altered in different cancer entities such as 
glioma [33]. As several pharmacological tools for the inhibi-
tion of Ephrin signaling including those targeting EPHA5 
have been tested for other diseases, this might be a good 
starting point for future studies on ATRT-SMARCA4 [14, 
21, 50].
Overall, based on the data presented here, we propose that 
ATRT-SMARCA4 should be regarded as a separate ATRT 
subgroup. As reported previously [17], they affect young 
children, who are often carriers of germline mutations. Addi-
tionally, the male predominance is even more pronounced 
and their global DNA methylation patterns as well as their 
global transcriptomics differ from the SMARCB1 mutated 
ATRT subgroups. The data are summarized in Fig. 2, which 
gives an overview on ATRT subgroups including the here 
described new findings. In future studies, these findings 
might be used to adjust therapeutic options in the clinic and 
consequently improve the survival of patients.
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